Bitter melon
Momordica charantia L.
Bitter melon (Momordica charantia) is an annual climbing vine with a warty, distinctly bitter fruit that contains charantin (sterol glucosides) and cucurbitane triterpenoids such as momordicosides. It is a well-known vegetable and folk remedy extensively studied for blood-glucose support.
No ratings yet — be the first!
Gallery
Overview
Bitter melon is an annual herbaceous vine 2–5 m long with ribbed, branching stems and tendrils for climbing. Its alternate leaves are deeply palmately lobed with toothed margins. The plant is monoecious, with solitary yellow male and female flowers in leaf axils. The fruit is a tapering, warty pepo: green when young, turning orange-yellow at maturity and splitting into three valves to reveal brown seeds wrapped in fleshy red arils. Young fruits are harvested about 12–20 days after fruit set.
According to Kew POWO, the native range of Momordica charantia spans the Tropical and Subtropical Old World to the South Pacific; the species is thought to have originated in Africa and Asia and to have been domesticated in Southeast Asia. It is now cultivated and naturalised throughout tropical and subtropical Asia, Africa, the Americas, the Caribbean and Oceania, sometimes becoming an invasive weed. Varieties differ markedly in fruit shape and bitterness.
Bitter melon contains more than 200 compounds; the most studied are cucurbitane triterpenoids (karaviloside XI, momordicosides S and T) and charantin — a mixture of the sterol glucosides β-sitosterol 3-O-β-D-glucoside and 5,22-stigmasterol 3-O-β-D-glucoside. It also contains polypeptide-p (an insulin-like peptide), vicine, saponins, flavonoids and minerals. Mechanistically, cucurbitanes promote GLUT4 translocation in muscle and adipose cells through the AMPK pathway (not PI3K/Akt), inhibit protein tyrosine phosphatase and lower postprandial glucagon; charantin and derivatives enhance insulin secretion and improve insulin resistance.
The unripe fruit is a common vegetable across Asia (stir-fried, in soups, stuffed, or eaten raw) and a folk remedy for diabetes in India, China and Vietnam. Clinical evidence is growing: a GRADE-adherent meta-analysis published in 2025 pooling 25 randomised controlled trials found that bitter melon lowered fasting glucose (SMD −0.46), HbA1c (−0.57), insulin (−0.48) and HOMA-IR (−0.52), with no effect on beta-cell function (HOMA-β). A 12-week trial in Korean prediabetes reduced post-load glucose and suppressed glucagon, while another trial lowered fasting glucose but not HbA1c. Because preparations are not standardised, results remain inconsistent across studies.
The unripe fruit is safe as food, but seeds and red arils are best removed for heavy use: seeds and ripe fruit contain cucurbitacins and vicine, and large intakes may cause vomiting or diarrhoea. Vicine/convicine can trigger haemolysis in people with G6PD deficiency (favism), who should avoid it. Bitter melon may cause additive hypoglycaemia with antidiabetic drugs and requires monitoring. The species is not globally threatened (IUCN: Least Concern – LC), is widespread across the tropics, widely cultivated and sometimes naturalised as a weed; medicinal supply comes mainly from cultivation.
Life cycle
From seed to productSeed
Hard seeds are sown directly; soaking in warm water speeds germination in 5–10 days.
Vine
The vine grows fast, climbing a trellis by tendrils and producing many leaves and yellow flowers.
Flowering – fruiting
Unisexual yellow flowers; green warty young fruits grow fast and are picked after 12–20 days.
Ripe fruit
Fruit turns orange-yellow and splits into three, revealing red seeds, kept for seed or harvest.
Distribution & origin
Share of recorded occurrences by region- South Asia (India · Bangladesh · Pakistan · Sri Lanka)25%
- Southeast Asia (Vietnam · Thailand · Indonesia · Philippines…)25%
- East Asia (China · Korea · Japan)15%
- Africa (tropical)20%
- Americas & Caribbean (introduced)8%
- Pacific & Australia7%
Chemical composition
Relative content in agarwood resin- Charantin (β-sitosterol & stigmasterol glucosides)Sterol glucosides studied for glycaemia28%
- Momordicosides S/T · karaviloside XI (cucurbitanes)GLUT4 up-regulation via AMPK22%
- Polypeptide-pInsulin-like peptide (p-insulin)12%
- Vicine & nucleosidesIn seeds; caution in G6PD deficiency10%
- Flavonoids & phenolicsQuercetin, catechin — antioxidant15%
- Others (vitamins, minerals, cucurbitacins)Micronutrients and bitter principles13%
Uses
- Culinary vegetable: stir-fried, in soups, stuffed or raw
- Traditional blood-sugar remedy (India · China · Vietnam)
- Standardised extracts/capsules as supplements for prediabetes and type 2 diabetes
- Decoctions of vines and leaves for bathing, cooling
- Active-compound research: charantin, momordicosides, mcIRBP-19 peptide
- Grown on trellises as an ornamental screen
Properties
- Fruit
- Long, warty; ripe orange-yellow, splitting
- Leaf
- Deeply lobed, toothed
- Seed
- Hard, in red aril when ripe
Habitat & conservation
Humid tropical and subtropical zones, from near sea level to about 1,000 m; a sun-loving climber favouring warm, well-drained soils on trellises, fences, home gardens and waste ground; it grows vigorously in the rainy season.
Conservation
Momordica charantia is not globally threatened (IUCN: Least Concern – LC). It is widespread across the tropics and subtropics, widely cultivated and often naturalised, sometimes becoming an invasive weed; medicinal supply comes mainly from cultivation, so wild populations face little pressure.
References
- 1Plants of the World Online — Momordica charantia L. — Royal Botanic Gardens, Kew, 2024
- 2Efficacy of Momordica charantia in glycaemic control and insulin resistance among patients with prediabetes and type 2 diabetes: a GRADE-adherent meta-analysis of randomised controlled trials — PubMed / Systematic Review, 2025
- 3Kim B.K. et al. Momordica charantia efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week randomised clinical study. Food Sci Biotechnol 32(5):697–704 — Food Science and Biotechnology, 2022
- 4Kim S.K. et al. Hypoglycemic efficacy and safety of Momordica charantia in patients with type 2 diabetes mellitus. Complement Ther Med 52:102524 — Complementary Therapies in Medicine, 2020
- 5Zänker et al. Momordica charantia L. — Diabetes-Related Bioactivities, Quality Control and Safety Considerations — PMC / Phytochemistry Reviews, 2022
- 6Basch E. et al. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 60(4):356–359 — American Journal of Health-System Pharmacy, 2003
- 7Yang Y.S. et al. A randomised, double-blind, placebo-controlled trial of mcIRBP-19-containing Momordica charantia fruit extract in type 2 diabetic subjects. Food Nutr Res 66 — Food & Nutrition Research, 2022
- 8Tan M.J. et al. Cucurbitane triterpenoids from Momordica charantia and GLUT4 translocation via AMPK (cited in Phytochem Rev review) — Phytochemistry Reviews, 2008
